Half-year report · HY
7459.TEDINET S100X3SK
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.90T | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥3.67T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.82T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥25.1bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥27.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥34.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥65.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥35.1bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥39.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥39.8bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥22.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥40.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥21.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥27.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥27.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.91T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.82T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.88T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.14T | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥1.07T | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥766.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥757.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥757.7bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥276.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥261.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥274.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥259.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥249.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥228.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥60.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥5.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥16.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥14.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥106.8 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥193.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.94 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | ¥160m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥625.1bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥625.0bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥139m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥13.9bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.22T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.21T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.8bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥9.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥1.90T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥1.90T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥24.9bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥161m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥600.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥600.2bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥201m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.0bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.17T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.17T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.83T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.82T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥27.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 512
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation sga | InterimDuration | 6722000000 | JPY |
| Other sga | Prior1InterimDuration | 25251000000 | JPY |
| Other sga | InterimDuration | 29260000000 | JPY |
| Selling general and administrative expenses | Prior1InterimDuration | 99278000000 | JPY |
| Selling general and administrative expenses | InterimDuration | 105196000000 | JPY |
| Operating income | Prior1InterimDuration | 27162000000 | JPY |
| Operating income | InterimDuration | 25083000000 | JPY |
| Interest income noi | Prior1InterimDuration | 12000000 | JPY |
| Interest income noi | InterimDuration | 88000000 | JPY |
| Dividends income noi | Prior1InterimDuration | 1565000000 | JPY |
| Dividends income noi | InterimDuration | 1690000000 | JPY |
| Research fee income noi | Prior1InterimDuration | 4260000000 | JPY |
| Research fee income noi | InterimDuration | 4316000000 | JPY |
| Real estate rent noi | Prior1InterimDuration | 1223000000 | JPY |
| Real estate rent noi | InterimDuration | 1275000000 | JPY |
| Equity in earnings of affiliates noi | Prior1InterimDuration | 606000000 | JPY |
| Equity in earnings of affiliates noi | InterimDuration | 2220000000 | JPY |
| Other noi | Prior1InterimDuration | 1241000000 | JPY |
| Other noi | InterimDuration | 1357000000 | JPY |
| Non operating income | Prior1InterimDuration | 8909000000 | JPY |
| Non operating income | InterimDuration | 10948000000 | JPY |
| Interest expenses noe | Prior1InterimDuration | 3000000 | JPY |
| Interest expenses noe | InterimDuration | 6000000 | JPY |
| Rent expenses on real estates noe | Prior1InterimDuration | 826000000 | JPY |
| Rent expenses on real estates noe | InterimDuration | 1157000000 | JPY |
| Loss on investments in partnership noe | Prior1InterimDuration | 24000000 | JPY |
| Loss on investments in partnership noe | InterimDuration | 453000000 | JPY |
| Other noe | Prior1InterimDuration | 137000000 | JPY |
| Other noe | InterimDuration | 144000000 | JPY |
| Non operating expenses | Prior1InterimDuration | 991000000 | JPY |
| Non operating expenses | InterimDuration | 1762000000 | JPY |
| Ordinary income | Prior1InterimDuration | 35080000000 | JPY |
| Ordinary income | InterimDuration | 34269000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1InterimDuration | 1000000 | JPY |
| Gain on sales of noncurrent assets ei | InterimDuration | 0 | JPY |
| Gain on sales of investment securities ei | Prior1InterimDuration | 4912000000 | JPY |
| Gain on sales of investment securities ei | InterimDuration | 9938000000 | JPY |
| Other ei | Prior1InterimDuration | 69000000 | JPY |
| Other ei | InterimDuration | 481000000 | JPY |
| Extraordinary income | Prior1InterimDuration | 4983000000 | JPY |
| Extraordinary income | InterimDuration | 10419000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | Prior1InterimDuration | 28000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | InterimDuration | 24000000 | JPY |
| Impairment loss el | Prior1InterimDuration | 168000000 | JPY |
| Impairment loss el | InterimDuration | 369000000 | JPY |
| Business structure improvement expenses el | Prior1InterimDuration | － | JPY |
| Business structure improvement expenses el | InterimDuration | 4291000000 | JPY |
| Other el | Prior1InterimDuration | 93000000 | JPY |
| Other el | InterimDuration | 193000000 | JPY |
| Extraordinary loss | Prior1InterimDuration | 290000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |